Screener
Fractyl Health GUTS Q3 2026 earnings
Reported November 12, 2026 · After market close
EPS-$1.07Beat by $0.43
EPS estimate-$1.50
“Armed with positive data, we have focused the Company around Revita's post-GLP-1 weight maintenance opportunity. We expect the capital we have today to be sufficient to fund our planned De Novo submission and upcoming 12-month pivotal data and. Our goal is for Revita to potentially establish an entirely new therapeutic category of post-GLP-1 weight maintenance by aiming to reverse years of diet-induced damage to the gut.”
Next report
Date not yet announcedVersus estimates
Diluted EPS
FAQ
- When did Fractyl Health report Q3 2026 earnings?
- Fractyl Health (GUTS) reported Q3 2026 earnings on November 12, 2026 after market close.
- What were Fractyl Health's Q3 2026 revenue and EPS?
- Fractyl Health reported eps of $-1.07 for Q3 2026.
- Did Fractyl Health beat estimates in Q3 2026?
- EPS beat the consensus estimate of $-1.50 by $0.43.
- How did Fractyl Health's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps declined 205.7% from $-0.35.
- Where can I find Fractyl Health's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-458308) and the 10-Q periodic report (0001193125-26-458318) directly on SEC EDGAR. The filing index links above go to sec.gov.
